Literature DB >> 24577126

Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.

Hye Kyung Han1, Hyungmi An, Kwang-Hee Shin, Donghoon Shin, Sue Hyun Lee, Ju Han Kim, Sang-Heon Cho, Hye-Ryun Kang, In-Jin Jang, Kyung-Sang Yu, Kyoung Soo Lim.   

Abstract

BACKGROUND: High doses of vancomycin increase the risk of nephrotoxicity, but the quantitative relationship between vancomycin exposure and nephrotoxicity is still controversial. This study evaluated the relationship between vancomycin trough concentration and nephrotoxicity, and risk factors for nephrotoxicity in patients undergoing therapeutic drug monitoring.
METHODS: A total of 1269 cases from patients who underwent therapeutic drug monitoring were collected from 2006 to 2010. Receiver operating characteristic curve analysis was used to evaluate the relationship between trough concentration and the incidence of nephrotoxicity. Logistic regression using the generalized Least Absolute Shrinkage and Selection Operator (lasso) method was used to evaluate possible risk factors for nephrotoxicity. The data were divided into high/low-concentration groups by the cutoff value obtained from the receiver operating characteristic curve, and additional logistic regression using the generalized lasso method was performed for each group.
RESULTS: The cutoff value of the vancomycin trough concentration was 12.1 mg/L. Patients with high concentrations (>12.1 mg/L) were more likely to develop nephrotoxicity (odds ratio = 16.0, 95% confidence interval, 8.2-31.1). The vancomycin trough concentration was the only significant risk factor for nephrotoxicity identified using the generalized lasso (P < 0.001). In contrast, no factor was associated with nephrotoxicity in the low-concentration group.
CONCLUSIONS: Vancomycin trough concentrations over 12.1 mg/L were associated with an increased risk of nephrotoxicity. This is lower than the known threshold. Trough vancomycin concentration over the threshold was the only risk factor of nephrotoxicity among demographic factors, dosing regimen, and other clinical conditions in this study. It is suggested that vancomycin trough concentrations greater than 12.1 mg/L require close monitoring for nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24577126     DOI: 10.1097/FTD.0000000000000061

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy.

Authors:  Claire Triffault-Fillit; Florent Valour; Ronan Guillo; Michel Tod; Sylvain Goutelle; Sébastien Lustig; Michel-Henry Fessy; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

2.  Elevated Vancomycin Trough Levels in a Tertiary Health System: Frequency, Risk Factors, and Prognosis.

Authors:  Reza Zonozi; Aozhou Wu; Jung-Im Shin; Alex Secora; Josef Coresh; Lesley A Inker; Alex R Chang; Morgan E Grams
Journal:  Mayo Clin Proc       Date:  2019-01       Impact factor: 7.616

3.  Application of Pharmacometrics in Pharmacotherapy: Open-Source Software for Vancomycin Therapeutic Drug Management.

Authors:  Soo Hyeon Bae; Dong-Seok Yim; Hyemi Lee; Ae-Ryoung Park; Ji-Eun Kwon; Hirata Sumiko; Seunghoon Han
Journal:  Pharmaceutics       Date:  2019-05-09       Impact factor: 6.321

4.  Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients.

Authors:  Yun Kim; Soohyun Kim; Jinsook Park; Howard Lee
Journal:  J Pers Med       Date:  2022-01-26

5.  Pharmacokinetic assessment of vancomycin in critically ill patients and nephrotoxicity prediction using individualized pharmacokinetic parameters.

Authors:  Parisa Ghasemiyeh; Afsaneh Vazin; Farid Zand; Elham Haem; Iman Karimzadeh; Amir Azadi; Mansoor Masjedi; Golnar Sabetian; Reza Nikandish; Soliman Mohammadi-Samani
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

6.  ELISA-based detection of gentamicin and vancomycin in protein-containing samples.

Authors:  Jim C E Odekerken; Dorien M W Logister; Loubna Assabre; Jacobus J C Arts; Geert H I M Walenkamp; Tim J M Welting
Journal:  Springerplus       Date:  2015-10-15

7.  Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions.

Authors:  John David Clements; Juan Jose Perez Ruixo; John P Gibbs; Sameer Doshi; Carlos Perez Ruixo; Murad Melhem
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.